KR20130067243A - 감소된 반응물 비율을 이용하여 ｐｅｇ-헤모글로빈 접합물을 제조하는 방법 - Google Patents

감소된 반응물 비율을 이용하여 ｐｅｇ-헤모글로빈 접합물을 제조하는 방법 Download PDF

Info

Publication number
KR20130067243A
KR20130067243A KR1020127025030A KR20127025030A KR20130067243A KR 20130067243 A KR20130067243 A KR 20130067243A KR 1020127025030 A KR1020127025030 A KR 1020127025030A KR 20127025030 A KR20127025030 A KR 20127025030A KR 20130067243 A KR20130067243 A KR 20130067243A
Authority
KR
South Korea
Prior art keywords
peg
concentration
mal
conjugate
hemoglobin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127025030A
Other languages
English (en)
Korean (ko)
Inventor
아쇼크 마라바리
킴 디. 밴드그리프
Original Assignee
생가트, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 생가트, 인코포레이티드 filed Critical 생가트, 인코포레이티드
Publication of KR20130067243A publication Critical patent/KR20130067243A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127025030A 2010-02-25 2011-02-23 감소된 반응물 비율을 이용하여 ｐｅｇ-헤모글로빈 접합물을 제조하는 방법 Withdrawn KR20130067243A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30823810P 2010-02-25 2010-02-25
US61/308,238 2010-02-25
PCT/US2011/025888 WO2011106396A1 (en) 2010-02-25 2011-02-23 Methods for preparing peg-hemoglobin conjugates using reduced reactant ratios

Publications (1)

Publication Number Publication Date
KR20130067243A true KR20130067243A (ko) 2013-06-21

Family

ID=44507180

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127025030A Withdrawn KR20130067243A (ko) 2010-02-25 2011-02-23 감소된 반응물 비율을 이용하여 ｐｅｇ-헤모글로빈 접합물을 제조하는 방법

Country Status (8)

Country Link
US (1) US9493616B2 (enExample)
EP (1) EP2539715B1 (enExample)
JP (1) JP2013520512A (enExample)
KR (1) KR20130067243A (enExample)
CN (1) CN102859364A (enExample)
AU (2) AU2011220885A1 (enExample)
CA (1) CA2791122C (enExample)
WO (1) WO2011106396A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013240141B2 (en) 2012-03-29 2017-11-02 Sangart, Inc. Diaspirin crosslinked PEGgylated hemoglobin
US20150094267A1 (en) * 2012-04-03 2015-04-02 Kim D. Vandegriff Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins
AU2018304174B2 (en) 2017-07-18 2025-07-10 VirTech Bio, Inc. Blood substitutes comprising hemoglobin and methods of making
WO2022184005A1 (en) 2021-03-01 2022-09-09 Billion King International Limited Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof
US20250064724A1 (en) * 2021-11-18 2025-02-27 Virginia Commonwealth University Modular field-stable bio-artificial blood substitute
WO2025219465A1 (en) * 2024-04-19 2025-10-23 Danmarks Tekniske Universitet Hemoglobin-based oxygen carrier

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2161086B2 (de) 1971-12-09 1975-04-24 Anton Cramer & Co, 4402 Greven Daunen- und federndichtes Gewebe
DE2449885C3 (de) 1974-10-21 1980-04-30 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat
US4001200A (en) 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4001401A (en) 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4529719A (en) 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
CA1312009C (en) 1986-11-10 1992-12-29 Carl W. Rausch Extra pure semi-synthetic blood substitute
US5449759A (en) 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US5234903A (en) 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US5650388A (en) 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5585484A (en) * 1995-04-19 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Hemoglobin crosslinkers
DE69831248T2 (de) 1997-02-28 2006-04-13 The Regents Of The University Of California, Oakland Verfahren und zusammensetzungen zur optimierung des sauerstofftransportes in zellfreien systemen
CN1332646A (zh) * 1998-10-15 2002-01-23 桑伽特股份有限公司 生产无基质血红蛋白的方法
US7019117B2 (en) * 2001-07-19 2006-03-28 Albert Einstein College Of Medicine Of Yeshiva University Size enhanced hemoglobins: surface decoration and crosslinking of the protein with polyoxy alkylene glycols
US20030153491A1 (en) * 2002-01-11 2003-08-14 Winslow Robert M. Methods and compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin
US7144989B2 (en) * 2002-03-25 2006-12-05 Albert Einstein College Of Medicine Of Yeshiva University Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof
JP2006514652A (ja) * 2002-12-23 2006-05-11 イェシバ・ユニバーシティ 修飾ヘモグロビンおよびこれの調製方法
CN1219811C (zh) * 2003-01-22 2005-09-21 中国科学院过程工程研究所 带单甲氧基聚乙二醇长尾的蛋白质修饰剂及制法和用途
JP2006519235A (ja) * 2003-02-26 2006-08-24 インターミューン インコーポレイティッド ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
CA2578232C (en) 2004-08-31 2015-12-29 Sangart, Inc. Methods to enhance hemodynamic stability using oxygen carrying compositions
WO2006096774A2 (en) 2005-03-07 2006-09-14 Sangart, Inc. Composition and methods for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers
WO2008136888A2 (en) * 2007-03-13 2008-11-13 Albert Einstein College Of Medicine Of Yeshiva University Second generation low oxygen affinity pegylated hemoglobins as oxygen-carrying plasma expanders
US8021858B2 (en) 2008-09-22 2011-09-20 Sangart, Inc. Method for making polyalkylene oxide modified hemoglobin
US20130041134A1 (en) 2009-11-05 2013-02-14 Sangart ,Inc. Methods for preparing polyethylene glycol maleimide using n-(2-hydroxyethyl) maleimide as a starting material

Also Published As

Publication number Publication date
EP2539715A1 (en) 2013-01-02
CN102859364A (zh) 2013-01-02
EP2539715A4 (en) 2016-03-02
JP2013520512A (ja) 2013-06-06
US20130217860A1 (en) 2013-08-22
CA2791122A1 (en) 2011-09-01
AU2017232073A1 (en) 2017-10-12
AU2011220885A1 (en) 2012-09-06
US9493616B2 (en) 2016-11-15
CA2791122C (en) 2019-08-27
WO2011106396A1 (en) 2011-09-01
EP2539715B1 (en) 2021-12-22
AU2017232073B2 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
AU2017232073B2 (en) Methods for preparing PEG-hemoglobin conjugates using reduced reactant ratios
KR102076874B1 (ko) 숙신이미드-활성화 나이트록실 화합물 및 단백질의 나이트록실화를 위한 이의 사용 방법
JP6668515B2 (ja) ジアスピリン架橋ｐｅｇヘモグロビン
EP2968597B1 (en) Polyalkylene oxide valerate hemoglobin conjugates
US8609815B2 (en) Methods for preparing stable deoxygenated PEG-hemoglobin conjugate solutions comprising an antioxidant
HK1177255A (en) Methods for preparing peg-hemoglobin conjugates using reduced reactant ratios
US20120282236A1 (en) Method of delivering oxygen using peg-hemoglobin conjugates with enhanced nitrite reductase activity
HK40008755A (en) Diaspirin crosslinked pegylated hemoglobin

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120925

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid